Zealand Pharma A/S’s (ZLDPF) Neutral Rating Reiterated at Cantor Fitzgerald

Zealand Pharma A/S (OTCMKTS:ZLDPF)‘s stock had its “neutral” rating reaffirmed by stock analysts at Cantor Fitzgerald in a report issued on Friday.

A number of other equities research analysts have also recently commented on the stock. BTIG Research raised shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th. Four equities research analysts have rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Zealand Pharma A/S currently has a consensus rating of “Buy”.

Zealand Pharma A/S Stock Performance

OTCMKTS ZLDPF opened at $57.67 on Friday. The firm has a market cap of $4.10 billion, a P/E ratio of 4.22 and a beta of 0.75. Zealand Pharma A/S has a 52-week low of $49.98 and a 52-week high of $101.29. The business’s 50-day moving average price is $64.96 and its 200 day moving average price is $70.77. The company has a quick ratio of 14.10, a current ratio of 14.10 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.34) by $0.53. The firm had revenue of $10.79 million during the quarter, compared to the consensus estimate of $19.69 million. Zealand Pharma A/S had a return on equity of 49.76% and a net margin of 70.06%. On average, equities research analysts expect that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.